Background: Although alopecia areata is a common disorder, it has no US Food and Drug Administration–approved treatment and evidence-based therapeutic data are lacking. Objective: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. Methods: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. Results: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. Limitations: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. Conclusion: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.
Bibliographical noteFunding Information:
Supported in part by the Duke University Hair Disorders Research and Treatment Center and the Leirion Foundation.
© 2017 American Academy of Dermatology, Inc.
- ALODEX score
- SALT score
- alopecia areata
- assessment measures
- outcome measures
- response criteria